Good morning Wake-Up Watchlisters! While you’re sipping coffee you’ll see stock futures dipped on Monday. Investors are still weary about inflation numbers after Federal Reserve Governor Christopher Waller said that policymakers have ‘a ways to go’ before ending interest-rate hikes. While signs of cooling inflation led the S&P 500 to its best week since June last week, it appears we’re not out of the woods yet.

With the markets still volatile, it’s tough to know exactly when they will head back up… consistently. That’s why it’s important to pay attention to what insiders DO rather than what they SAY. Tracking insider buying is exactly what our Head Fundamental Tactician Karim Rahemtulla does as part of his Insider Matrix. And this week, he’s revealing his ‘InsiderCode’ strategy that will show you exactly how to apply this powerful trading strategy in real time. You’ll be able to see trades as they happen, including Karim’s 3 favorite insider plays right now.

Click here to get on the list.

Here’s a look at the top-moving stocks this morning.

Opiant Pharmaceuticals (Nasdaq: OPNT)

Opiant Pharmaceuticals is up 119.89% premarket after agreeing to be acquired by Indivior PLC (INDV). Under the agreement, Indivior will acquire all of the outstanding shares of Opiant for upfront consideration of $20 per share. The acquisition will expand indivior’s portfolio of addiction therapies and leverage its expertise and resources to maximize the launch of OPNT003, a potential treatment for opioid overdose.

Redhill Biopharma (Nasdaq: RDHL)

Redhill Biopharma is up 23.27% premarket after the company reached an agreement in principle with HCR Collateral Management to extinguish all debt obligations in exchange for the transfer of RedHill’s rights in Movantik™ (naloxegol). It is expected that RedHill would provide transition services to HCR to ensure a seamless process so patient care will not be interrupted.

MorphoSys AG (Nasdaq: MOR)

MorphoSys is down 29.01% premarket after partner Roche says its Alzheimer’s drug trials didn’t meet its goals. The experimental medicine, galled gantenerumab, didn’t slow clinical decline in people with early Alzheimer’s, the Swiss drugmaker said Monday. Overall, the medicine didn’t match the success of Biogen Inc. and Eisai Co’s lecanemab, as it removed less beta amyloid protein than researchers had expected in patient’s brains.

Medical innovations don’t always come to fruition, but when they do, there can be massive gains to be made. See why our friend Alexander Green is so high on this one medical device that’s been called ‘humanity’s next big leap.’ Elon Musk recently sent this device into orbit and right now you can get in for just $3.

Click here to discover this game-changing medical stock.

Dentsply Sirona Inc. (Nasdaq: XRAY)

Dentsply is down 10.76% premarket after the company suffered a $1.08 billion net loss in the third quarter of 2022. The dental products maker cut its full-year outlook, citing weaker demand, supply chain challenges and unfavorable currency translation.

As more and more companies suffer losses in 2022, it’s crucial to look at other ways to invest outside of the stock market. See why one of the world’s most popular ‘inflation-proof’ assets could be banned in America soon, and why you should move your money by December 14, 2022.

Click here to learn how to protect your assets.

Those are the top market movers today.

Happy trading!

The Wake-Up Watchlist Research Team